Clinical-grade whole genome sequencing, once available only to wealthy patients in specialized programs, is now accessible to anyone for $599 through a new offering called Genomics for All. The product sequences all 6.4 billion base pairs of an individual's DNA and delivers AI-interpreted results through a mobile app, with no clinic visit required. This represents a significant shift in how genomic data becomes actionable health information for the general public.

What Makes This Different From Consumer DNA Tests?

Most people are familiar with ancestry DNA tests like 23andMe or AncestryDNA, but those services analyze less than 0.02% of your genome using a technology called SNP chip sequencing. Genomics for All takes a fundamentally different approach. It sequences the entire genome at 30x clinical-grade depth, the coverage standard required for medically meaningful interpretation. This depth of analysis enables the platform to identify inherited disease risk across more than 10,000 genetic variants, flag pharmacogenomic markers that affect how you respond to common medications like statins and GLP-1 receptor agonists, and screen for carrier status in hereditary conditions.

The report also covers health-related traits across nutrition, metabolism, and exercise response. Wei-Wu He, Chairman and CEO of Human Longevity, explained the company's vision for the product.

"Our founder Dr. Venter helped make it possible for humanity to read the human genome. With Genomics for All, we are continuing that vision by helping more people understand what their genome may mean for their long-term health. Our goal is not to replace physicians or make deterministic predictions, but to provide better information that can support more informed conversations, earlier awareness, and more personalised care," said Wei-Wu He.

Wei-Wu He, Chairman and CEO of Human Longevity, Inc.

How Does the AI Re-Analysis Feature Work?

One of the most innovative aspects of Genomics for All is its AI-powered re-analysis capability. Because your genome itself does not change, Human Longevity re-analyzes each client's genomic data on an ongoing basis as new research is published, new disease-gene associations are identified, and clinical guidelines are updated. When a new clinically relevant finding emerges, the company proactively alerts affected clients, often within 24 hours of publication. This transforms a one-time sequencing event into a continuously evolving health resource that adapts as science advances.

Steps to Understanding Your Genomic Results

• Initial Sequencing: Your DNA is sequenced at clinical-grade depth, analyzing all 6.4 billion base pairs to identify disease risk variants and medication response markers.
• AI Interpretation: Machine learning algorithms interpret your results and flag clinically relevant findings, delivered through the HLI app without requiring a doctor's visit.
• Ongoing Monitoring: Your data is automatically re-analyzed as new research emerges, with alerts sent to you when new findings relevant to your genome become available.
• Informed Conversations: Results are designed to support discussions with your healthcare provider, enabling more personalized care decisions based on your genetic profile.

What's Behind the Technology?

Genomics for All sits within a broader AI-driven platform that Human Longevity has been building for over a decade. In May 2026, the company announced the launch of Human Life Foundation Models, Inc. (HLFM), a dedicated AI entity developed in partnership with Insilico Medicine, a clinical-stage generative AI biotechnology company. This multimillion-dollar collaboration aims to develop what the companies describe as the industry's first large-scale AI foundation model dedicated to longevity science.

The foundation model draws on Human Longevity's multimodal clinical and genomic datasets collected across more than 10,000 clients to identify the biological mechanisms of aging and enable predictive healthcare. The scientific advisory board includes Nobel laureates Dr. Geoffrey Hinton and Dr. Michael Levitt, lending credibility to the research underpinning the platform.

Where Does Genomics for All Fit in the Broader Market?

Genomics for All is positioned as the entry-level offering in Human Longevity's broader suite of precision health programs. The company also offers more comprehensive assessments that combine advanced imaging, biomarker panels, and clinician-guided care for clients seeking deeper health insights. Human Longevity was founded in 2013 by Dr. J. Craig Venter, a pioneering genomicist who led the private effort to sequence the human genome. The company has invested approximately $600 million in research and worked with more than 10,000 clients across its clinics in San Diego and San Francisco.

The $599 price point represents a democratization of genomic technology that was previously available only to wealthy individuals or research participants. By combining affordable sequencing with AI-powered interpretation and continuous re-analysis, Human Longevity is making personalized genomic medicine accessible to a much broader population. The product is available now at humanlongevity.com/genomics.